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Introduction
Increasing lines of evidence show that activation of
Kupffer cells plays a pivotal role in initiation and progres-
sion of alcoholic liver disease. Kupffer cell activation is
evoked by endotoxin (lipopolysaccharide, LPS), which
leads to rapid elevation of intracellular calcium accompa-
nied by release of a variety of mediators including
cytokines, eicosanoids and reactive radical species.
Among them, TNF-alpha is a critical factor in the patho-
genesis of alcoholic liver disease.
Thalidomide (alpha-N-phthalimidoglutarimide) was ini-
tially used as a sedative and antiemetic during pregnancy
but was withdrawn from the market due to its teratogenic
effects. Before it was banned, thalidomide was recognized
to reduce dramatically symptoms associated with ery-
thema nodosum leprosum, a complication of Hansen's
disease. Subsequently, it was shown that thalidomide sup-
presses TNF-alpha production by macrophages and other
cell types such as activated T cells [1,2], which was attrib-
uted to a mechanism of thalidomide action [3].
Accordingly, the purpose of this study was to determine
whether thalidomide could prevent alcohol-induced liver
injury. Here we report that thalidomide prevents liver
damage caused by chronic ethanol exposure through not
only suppression of TNF-alpha production but abroga-
tion of Kupffer cell sensitization to LPS.
Methods
Animals and Treatments
In this study, a model of alcoholic liver injury based on
the sensitization of Kupffer cells, in which rats are given
ethanol (5 g/kg body wt) once every 24 hours [4], was
used. This model achieves inflammatory and necrotic
changes in the liver only in 8 weeks, which mimics fea-
tures of clinical alcohol liver injury [5]. Liver damage was
evaluated after 8 weeks of ethanol since histological man-
ifestations are preceded by sensitization of Kupffer cells to
LPS treatment, and Kupffer cell sensitization to LPS was
evaluated at 4 weeks. Female Wistar rats weighing 200–
250 g were fed on a liquid diet (Oriental, Tokyo, Japan).
Two groups of rats received an oral dose of thalidomide (5
mg/kg body wt) only or concurrently with ethanol [6].
Gut permeability was measured in isolated segments of
ileum from translocation of horseradish peroxidase as
described previously [6].
Kupffer Cell Preparation Culture, Measurement of [Ca2+]i, 
and TNF-alpha Production
Kupffer cells were isolated by collagenase digestion and
[Ca2+]i was measured using a microspectrofluorometer
with fura-2, and TNF-alpha in the culture media was
measured using an enzyme-linked immunosorbent assay
(ELISA) kit (Genzyme, Cambridge, MA).
Statistical Analysis
All results were expressed as mean ± S.E.M. Statistical dif-
ferences between means were determined using analysis
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post-hoc test or Student's t test as appropriate. p < 0.05
was selected prior to the study to reflect significance.
Results
Effect of Thalidomide on Alcoholic Liver Injury
Ethanol administration once every 24 h for 8 weeks
caused pronounced pathological changes in the liver lob-
ule, including steatosis, necrosis and inflammation in the
liver, confirming our earlier results. In marked contrast,
these pathological changes were prevented almost com-
pletely by coadministration of thalidomide (5 mg/kg).
Likewise, ALT was increased to 91 ± 7 IU/L in the 8-week
ethanol group, which was three times higher than the val-
ues in the control, non-treated rats (Table 1). The increase
in ALT was prevented completely by thalidomide. Similar
results were obtained for AST values.
Effect of Thalidomide on Ethanol plus LPS-Induced Liver 
Injury
In an attempt to evaluate the sensitization of Kupffer cells
to LPS in vivo, LPS (5 mg/kg) was administered i.v. and
liver histology were evaluated 24 hours later (data not
shown). LPS caused focal necrosis with neutrophil infil-
tration in the control liver. In the group treated with tha-
lidomide for 4 weeks, liver histology revealed only slight
infiltration of neutrophils, but lacking evidence of necro-
sis. This result agrees with serum transaminase levels,
which were slightly lower in the thalidomide-only group.
In the 4-week ethanol group, LPS injection resulted in
marked aggravation of these pathological parameters.
Moreover, steatosis was prominent in this group. Treat-
ment with thalidomide dramatically improved liver
injury, which exhibited near normal histology. The
increased ALT levels observed 24 hours after LPS injection
in the 4-week ethanol group was blocked completely by
thalidomide. Similar results were obtained with AST val-
ues (Table 2).
Effect of Thalidomide and Ethanol on LPS-Induced 
Increases in [Ca2+]i and TNF-alpha Production in Isolated 
Kupffer Cells
To further determine the effect of thalidomide of ethanol-
induced Kupffer cell sensitization to LPS, LPS-induced
increase of [Ca2+]i and LPS-induced production of TNF-
alpha were measured. As reported earlier, LPS evoked a
transient increase in [Ca2+]i of Kupffer cells obtained from
control rats from basal levels to 81 ± 13 nM. After the peak
increase, [Ca2+]i declined rapidly returning to basal value.
Thalidomide treatment did not alter the [Ca2+]i response.
In contrast, the LPS-induced peak [Ca2+]i elevation was
about 2 to 3-fold greater in Kupffer cells isolated from rats
given ethanol for 4 weeks. It was also noted that, after the
peak increase, [Ca2+]i started to decrease but remained ele-
vated over 180 sec. The increased [Ca2+]i response was
blocked completely by concurrent administration of
thalidomide with ethanol for 4 weeks. Moreover, TNF-
alpha production shows similar pattern (Table 3).
Effect of Ethanol and Thalidomide on CD14 Expression in 
the Liver
Because CD14, a functional LPS/LBP receptor, is critical
for signaling pathways leading to expression of cytokines,
eicosanoids and radical species in Kupffer cells, we meas-
ured CD14 with Western blotting (data not shown). Liver
from control rats expressed the 55 kD CD14. Thalidomide
did not change the amount of CD14 protein; however, the
band was far more intense in liver from rats treated with
ethanol chronically. Furthermore, the ethanol-induced
Table 1: Effect of thalidomide on ethanol-induced liver injury
ALT(IU/L) AST(IU/L)
Control 101 ± 12 30 ± 6
Thalido (5 mg/kg) 8 weeks 62 ± 3 38 ± 6
Ethanol (5 g/kg) 8 weeks 162 ± 7* 91 ± 7*
Ethanol + Thalidomide 8 weeks 126 ± 15** 37 ± 3**
* p < 0.05 vs. control, ** p < 0.05 vs. 8 weeks of ethanol
Table 2: Effect of thalidomide on ethanol plus LPS-induced liver 
injury.
AST(IU/L) ALT(IU/L)
LPS(5 mg/ml) 846 ± 227 483 ± 167
Thalido 4 weeks + LPS 307 ± 15 239 ± 15
Ethanol 4 weeks + LPS 2091 ± 295* 1200 ± 375*
Ethanol + Thalido 4 weeks + LPS 379 ± 231** 219 ± 179**
* p < 0.05 vs. LPS, ** p < 0.05 vs. 4 weeks of ethanol + LPS.
Table 3: Effect of ethanol and thalidomide on LPS-induced 
increases in intracellular Ca2+ and TNF-alpha production in 
isolated Kupffer cells.
[Ca2+]i (nM) TNF-alpha(pg/ml)
LPS (100 ng/ml) 85 ± 4 559 ± 71
Thalido 4 weeks + LPS 92 ± 6 578 ± 77
Ethanol 4 weeks + LPS 227 ± 26* 1104 ± 110*
Ethanol + Thalido 4 weeks + LPS 83 ± 4** 625 ± 72**
* p < 0.05 vs. control, ** p < 0.05 vs. 4 weeks of ethanol.Page 2 of 4
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with co-administration of thalidomide for 4 weeks.
Effects of Ethanol and Thalidomide on Gut Permeability
As reported previously, Kupffer cell sensitization to LPS is
caused by LPS. Therefore, we determined the effect of tha-
lidomide on gut-permeability (Table 4). Thalidomide
alone did not alter the basal value of gut permeability. In
marked contrast, two hours after the final ethanol treat-
ment in the 4 weeks group, gut permeability was increased
10-fold as compared to control values. The ethanol-
induced increase in gut permeability was, however, not
affected by treatment with thalidomide, As expected, LPS
levels in portal blood were not different between the eth-
anol-only and ethanol + thalidomide groups (140 ± 51
pg/ml vs. 99 ± 40 pg/ml, N.S.).
Effect of Thalidomide on LPS-Induced TNF-alpha mRNA 
Expression and TNF-alpha Production in Cultured Kupffer 
Cells
After addition of LPS (100 ng/ml) to Kupffer cells isolated
from the untreated, control rats, the amount of TNF-alpha
mRNA increased and reached a maximal value after 1
hour, followed by a gradual decline over 2 hours (data not
shown). Inclusion of thalidomide (5 micromolar) in the
culture media did not alter the peak level of TNF-alpha
mRNA occurring at 1 hour after LPS. However, 3 hours
after LPS addition, the amount of TNF-alpha mRNA in
Kupffer cells treated with thalidomide was 30% lower
than that of control Kupffer cells, indicating that thalido-
mide accelerated decrease in TNF-alpha mRNA (Table
5A). Thalidomide (5 micromolar) reduced production of
TNF-alpha by Kupffer cells challenged with LPS (100 ng/
ml) for 4 hours (Table 5B).
Effect of Thalidomide and TNF-alpha on Expression of 
CD14 in Cultured Kupffer Cells
To explore the mechanism by which thalidomide abro-
gated Kupffer cell sensitization to LPS caused by chronic
ethanol, we determined the effect of TNF-alpha on CD14
expression in Kupffer cells obtained from normal rats in
vitro (data not shown). Treatment with TNF-alpha (10 ng/
ml) for 24 hours resulted in enhancement of CD14
expression in Kupffer cells. Inclusion of thalidomide (5
micromolar) in the culture media reduced CD14 expres-
sion to a level comparable to the control.
Effect of Thalidomide and TNF-alpha on LPS-Induced 
TNF-alpha Production by Cultured Kupffer Cells
LPS-induced TNF-alpha production by isolated Kupffer
cells was compared between groups cultured for 24 hours
in the presence or absence of TNF-alpha (10 ng/ml) prior
to LPS challenge. Kupffer cells pretreated with TNF-alpha
produced about 30% more TNF-alpha in response to LPS
(100 ng/ml) than the control cells cultured in the absence
of TNF-alpha (Table 6). Thalidomide (5 micromolar)
completely blocked the TNF-alpha-induced enhancement
of TNF-alpha production by Kupffer cells in response to
LPS.
Discussion
The results of this study showed that thalidomide pre-
vented liver injury caused by chronic ethanol treatment
(Table 1). To investigate the mechanism of inhibitory
Table 4: Effect of ethanol and thalidomide treatment on gut 
permeability.
HRP(U/L)
Control 63 ± 6
Thalido 4 weeks 68 ± 12
Ethanol 4 weeks 591 ± 90*
Ethanol + Thalido 4 weeks 543 ± 161*
* p < 0.05 vs. control.
Table 5: Effect of thalidomide on LPS-induced TNF-alpha mRNA 
expression and TNF-alpha production in cultured Kupffer cells.
(A) TNF-alpha and beta-actin mRNA expression
TNF-alpha/beta-actin(%1 h LPS)
LPS (100 ng/ml) 1 hour 100
LPS + Thalido (5 micromolar) 1 
hour
97
LPS 3 hours 65
LPS + Thalido 3 hours 41
(B) TNF-alpha production
TNF-alpha (pg/ml)
LPS (100 ng/ml) 501 ± 19
LPS + Thalido (5 micromolar) 268 ± 4*
* p < 0.05 vs. control.
Table 6: Effect of thalidomide and TNF-alpha on LPS-induced 
TNF-alpha production by cultured Kupffer cells.
TNF-alpha (pg/ml)
LPS (100 ng/ml) 726 ± 82
TNF-alpha (10 ng/ml)+ LPS 936 ± 186*
Thalidomide (5 micromolar) + TNF-alpha + LPS 439 ± 105**
* p < 0.05 vs. TNF-alpha(-), ** p < 0.05 vs. TNF-alpha(+).Page 3 of 4
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effects of thalidomide against ethanol-induced liver
injury, we determined if thalidomide directly acted on
Kupffer cells thereby reducing TNF-alpha production. As
shown in Table 6, thalidomide did not affect the levels of
TNF-alpha mRNA in Kupffer cells after 1 hour of chal-
lenged with LPS, however, reduced later the amounts of
TNF-alpha mRNA. Consequently, the LPS-induced TNF-
alpha synthesis by Kupffer cells was inhibited by thalido-
mide. This result agrees with an earlier work showing that
thalidomide abrogated LPS-induced TNF-alpha produc-
tion from macrophages [1,2]. It was reported that thalid-
omide decreases TNF-alpha production by accelerating
the degradation of its mRNA [2].
TNF-alpha has a pleiotropic cytokine and regulatory
mechanisms of TNF-alpha production in macrophages
and its intracellular signaling have been studied exten-
sively [7]. It was suggested that TNF-alpha acts on macro-
phages/monocytes to promote its own synthesis and
secretion [8]. The fact that thalidomide destabilizes TNF-
alpha mRNA provides a good basis for the use of thalido-
mide to treat alcohol-induced liver injury because a recent
work by Kishore et al. revealed stabilization of TNF-alpha
mRNA by chronic ethanol [9]. We hypothesized that an
autocrine stimulation by TNF-alpha is involved in the
ethanol-induced Kupffer cell sensitization and that thalid-
omide interferes with this pathway, leading to abrogation
of Kupffer cell sensitization.
This scenario is supported by the facts that pretreatment
with TNF-alpha led to an increased TNF-alpha synthesis in
response to LPS and enhancement of CD14 expression in
Kupffer cells, and that inclusion of thalidomide in the
culture media inhibited this TNF-alpha-induced autocrine
activation of TNF-alpha synthesis (Table 6). Furthermore,
thalidomide blocked completely the TNF-alpha-induced
upregulation of CD14 in Kupffer cells in vitro.
The precise mechanisms of the thalidomide actions
remain to be pursued, however, the results of this study
suggest that thalidomide prevents liver injury caused by
chronic ethanol consumption through destabilization of
TNF-alpha mRNA and abolishing Kupffer cell sensitiza-
tion to LPS. Though currently its side effects preclude the
use of thalidomide in clinical settings and require rigors of
the drug distribution program and prescription decision,
efforts to synthesize thalidomide analogues lacking tera-
togenic effects but having more potent efficacy are under-
way [10]. Given that thalidomide has unique mechanisms
of actions, there appears to be a strong possibility that this
type of drug will prove beneficial to patients with severe
alcoholic liver injury.
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